What question did this study set out to answer?

The paper examines a rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient and its treatment response to crizotinib.

April 28, 2026SHILAP Revista de lepidopterología0 citationsOpen Access

View Full Paper

A rare KIFB5-ALK fusion variant in lung adenocarcionoma

KWKinga WiniarczykThe Maria Sklodowska-Curie National Research Institute of Oncology KSKatarzyna Seliga ATAgnieszka Tomczyk-SzatkowskaThe Maria Sklodowska-Curie National Research Institute of Oncology

Key Points

The paper examines a rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient and its treatment response to crizotinib.
Next-generation sequencing was used to identify the KIF5B-ALK fusion variant.
The patient was a 63-year-old male former smoker diagnosed with non-small-cell lung cancer.
Partial response to crizotinib treatment was monitored over 8 months.
The patient achieved a partial response to crizotinib treatment lasting 8 months.
No specific metrics were provided for treatment response effectiveness.

Abstract

Next-generation sequencing (NGS) has revealed an increase in the number of ALK anaplastic lymphoma kinase gene fusion variants. Clinical outcomes for patients with non-small-cell lung cancer (NSCLC) have improved significantly with the use of tyrosine kinase inhibitors (TKIs), but treatment outcomes vary, even for the same fusion variants; depending on the breakpoint. This article, presents the case of a 63-year-old male former smoker who was identified by NGS with a rare ALK fusion variant, namely KIF5B-ALK. The patient achieved a partial response (PR) to crizotinib treatment, which lasted 8 months.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

A rare KIFB5-ALK fusion variant in lung adenocarcionoma

Key Points

Abstract

Cite This Study

Also Consider

Also Consider